Loading
Total declarations
Company
▲ Purchases (6 ops.)
▼ Sales (0 ops.)
Latest filing published 09 Apr 2026 for Clover Biopharmaceuticals, Ltd. - B.
Insider track record
Disclosed buys
6
Disclosed sells
0
Signal history
No signal scores available.
Closed purchases
Market purchases
1
Not enough history yet: 0 closed purchases, at least 2 are needed.
Purchases by company
Since each purchase
- -35.4%Entry HK$2.85 · Close 05 Oct 2026 HK$1.84
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Leggett Thomas Edward: trading record in brief
Leggett Thomas Edward, listed as chief executive, appears in our data through filings on Clover Biopharmaceuticals, Ltd. - B shares, published by HKEX. Between 5 November 2021 and 2 April 2026, the trades on record add up to 14 filings.
No open-market sale appears; the market trades are 6 purchases. No amount is published for 6 filings, which the totals therefore leave out. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. In 2026 alone, the filings show 1 purchase and no sales.
The record was last updated on 9 April 2026 with a transaction in Clover Biopharmaceuticals, Ltd. - B. The latest purchase dates back some time: it was published 206 days ago, on 1 April 2026. The median gap between a trade and its publication by HKEX is 5 days. The shorter that gap, the sooner other investors can see what insiders have done. Every figure here comes from the filings published by HKEX and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Leggett Thomas Edward
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations2 total
49,000 sharesShareXHKGHKEX:DA20260409E00126
340,000 sharesShareXHKGHKEX:DA20260401E00056
Canonical exit: 25 Jun 2026 (T+90)
2 of 2 declarations
